» Articles » PMID: 38973850

Enhancing Therapeutic Efficacy in Cancer Treatment: Integrating Nanomedicine with Autophagy Inhibition Strategies

Overview
Journal ACS Omega
Specialty Chemistry
Date 2024 Jul 8
PMID 38973850
Authors
Affiliations
Soon will be listed here.
Abstract

The complicated stepwise lysosomal degradation process known as autophagy is in charge of destroying and eliminating damaged organelles and defective cytoplasmic components. This mechanism promotes metabolic adaptability and nutrition recycling. Autophagy functions as a quality control mechanism in cells that support homeostasis and redox balance under normal circumstances. However, the role of autophagy in cancer is controversial because, mostly depending on the stage of the tumor, it may either suppress or support the disease. While autophagy delays the onset of tumors and slows the dissemination of cancer in the early stages of tumorigenesis, numerous studies demonstrate that autophagy promotes the development and spread of tumors as well as the evolution and development of resistance to several anticancer drugs in advanced cancer stages. In this Review, we primarily emphasize the therapeutic role of autophagy inhibition in improving the treatment of multiple cancers and give a broad overview of how its inhibition modulates cancer responses. There have been various attempts to inhibit autophagy, including the use of autophagy inhibitor drugs, gene silencing therapy (RNA interference), and nanoparticles. In this Review, all these topics are thoroughly covered and illustrated by recent studies and field investigations.

Citing Articles

A Comprehensive Review of Nanoparticle-Based Drug Delivery for Modulating PI3K/AKT/mTOR-Mediated Autophagy in Cancer.

Rahman M, Jalouli M, Bhajan S, Al-Zharani M, Harrath A Int J Mol Sci. 2025; 26(5).

PMID: 40076496 PMC: 11899884. DOI: 10.3390/ijms26051868.


Graphene oxide-chloroquine conjugate induces DNA damage in A549 lung cancer cells through autophagy modulation.

Arya B, Mittal S, Joshi P, Pandey A, Ramirez-Vick J, Gupta G Beilstein J Nanotechnol. 2025; 16:316-332.

PMID: 40041432 PMC: 11878127. DOI: 10.3762/bjnano.16.24.


Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy.

Theivendren P, Kunjiappan S, Pavadai P, Ravi K, Murugavel A, Dayalan A ACS Meas Sci Au. 2025; 5(1):31-55.

PMID: 39991031 PMC: 11843507. DOI: 10.1021/acsmeasuresciau.4c00062.


Applications of polymeric nanoparticles in drug delivery for glioblastoma.

Liu S, Tan B, Wang F, Yu Y Front Pharmacol. 2025; 15():1519479.

PMID: 39834835 PMC: 11742935. DOI: 10.3389/fphar.2024.1519479.

References
1.
Efferth T . From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin Cancer Biol. 2017; 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. View

2.
Liechty W, Kryscio D, Slaughter B, Peppas N . Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2012; 1:149-73. PMC: 3438887. DOI: 10.1146/annurev-chembioeng-073009-100847. View

3.
Zheng Y, Su C, Zhao L, Shi Y . Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy. J Nanobiotechnology. 2017; 15(1):28. PMC: 5387274. DOI: 10.1186/s12951-017-0261-x. View

4.
Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L . Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release. 2017; 266:272-286. DOI: 10.1016/j.jconrel.2017.09.042. View

5.
Wang H, Zhao X, Guo C, Ren D, Zhao Y, Xiao W . Aptamer-Dendrimer Bioconjugates for Targeted Delivery of miR-34a Expressing Plasmid and Antitumor Effects in Non-Small Cell Lung Cancer Cells. PLoS One. 2015; 10(9):e0139136. PMC: 4583438. DOI: 10.1371/journal.pone.0139136. View